1 / 19

Minorities and the medically underserved in clinical trials

Minorities and the medically underserved in clinical trials. Edward L. Trimble, MD, MPH CTEP, DCTD, NCI. Why clinical trials need to be representative. We need definitive tests of interventions in the same people who have cancer or who are at risk of cancer.

adila
Download Presentation

Minorities and the medically underserved in clinical trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Minorities and the medically underserved in clinical trials Edward L. Trimble, MD, MPH CTEP, DCTD, NCI

  2. Why clinical trials need to be representative • We need definitive tests of interventions in the same people who have cancer or who are at risk of cancer. • Can we deliver the intervention in the community setting? • Do genetics, culture, SES, or co-morbidity affect toxicity or efficacy of treatment?

  3. Who has been under-represented on treatment trials?: I • Older patients, especially those 70+ with co-morbidity • Adolescent and young adults (ages 15-39) • African-American, Asian-American, Hispanic-American, and Native American men and women

  4. Who has been under-represented on treatment trials?: II • Residence in rural counties • Residence in counties with lower educational levels and higher unemployment rates • Difficulties with access to regular health care and centers with clinical trials

  5. Ongoing NCI initiatives focused in expanding accrual to trials • CCOP and MBCCOP programs • Cancer Disparities Research Partnership Program • National Community Cancer Center Program

  6. Overcoming Barriers Initiative • Early phase (I, II) trials at 7 NCI-designated Cancer Centers • Public-private partnership with Friends of Cancer Research and pharma • UC Davis: public, community, and professional education • U of Colorado/ Moffitt: patient navigators for older patients

  7. Overcoming Barriers: II • Washington University: patient navigators (‘coaches’) • OSU: community education, patient education, pre-screening via informatics, PC tablets for trial availability, informed consent ‘short forms’ in multiple languages

  8. Overcoming Barriers: III • Mass General: patient navigator/ research nurse in community hospital serving poor immigrants; education for translators • U of Pittsburgh: satellite clinics linked by telemedicine & informatics • San Antonio: survey of physicians serving Hispanic-American cancer patients

  9. NCI Office of Communications • Encompasses Office of Education and Special Initiatives • Education for health care professionals about clinical trials • Public and community education about clinical trials

  10. Partnerships • American Cancer Society • Centers for Disease Control and Prevention • Intercultural Cancer Council • Eliminating Disparities in Clinical Trials (EDICT): CLAS-ACT, BackPack • Lance Armstrong Foundation • Education Network to Advance Cancer Clinical Trials (ENACCT)

  11. NCI I2 Team on Cancer Health Disparities • I2: Integration and Implementation • Chair: Sanya Springfield, PhD • Currently drafting proposals to go to Dr. Niederhuber and NCI Executive Committee

  12. I2 CHD draft proposals: I • Include health disparities outcome as a primary or secondary objective in clinical trials • Where appropriate, integrate community-based participatory research approaches in clinical trials

  13. I2 CHD draft proposals: II • Require patients to self-report race and ethnicity consistent with OMB and US Census guidelines • Capture proxy measures of socio-economic status (SES) on all patients (educational level, census tract of residence)

  14. I2 CHD draft proposals: III • Oversample minority or underserved populations in phase III clinical trials for cancers which are more prevalent, whose outcomes are more severe, or for which biological indicators of differences underlie disparities • Increase per-capita reimbursement for complexity of case and trial

  15. I2 CHD draft proposals: IV • Collect information on barriers to and promoters of accrual to trials • Compile and disseminate best practices for clinical trials accrual and retention • Evaluate promising new strategies for accrual, using standardized criteria

  16. I2CHD draft proposals: V • Include accrual to health disparities research as a program/ project goal • Include effective accrual strategies among review criteria for new phase III trials and large cohort studies • Include appropriate funding for accrual and retention in awards (including bonus payments)

  17. I2 CHD draft proposals: VI • Evaluate institutional costs for recruitment and retention • Evaluate existing models: CCOPs, MBCCOPS, core facilities, patient navigators • Expand the use of effective models

  18. I2 CHD draft proposals: VII • Where appropriate and safe, expand eligibility criteria • Design trials for patients with co-morbidities • Strengthen cultural competence in design and conduct of clinical research

  19. Comments/ suggestions • Ken Chu (kc10d@nih.gov) • Worta McCaskill-Stevens (mccaskiw@mail.nih.gov) • Ted Trimble (tt6m@nih.gov)

More Related